JAMA Oncology submission guide
JAMA Oncology's submission process, first-decision timing, and the editorial checks that matter before peer review begins.
Associate Professor, Clinical Medicine & Public Health
Author context
Specializes in clinical and epidemiological research publishing, with direct experience preparing manuscripts for NEJM, JAMA, BMJ, and The Lancet.
Readiness scan
Before you submit to JAMA Oncology, pressure-test the manuscript.
Run the Free Readiness Scan to catch the issues most likely to stop the paper before peer review.
Key numbers before you submit to JAMA Oncology
Acceptance rate, editorial speed, and cost context — the metrics that shape whether and how you submit.
What acceptance rate actually means here
- JAMA Oncology accepts roughly ~8% of submissions — but desk rejection runs higher.
- Scope misfit and framing problems drive most early rejections, not weak methodology.
- Papers that reach peer review face a different bar: novelty, rigor, and fit with the journal's editorial identity.
What to check before you upload
- Scope fit — does your paper address the exact problem this journal publishes on?
- Desk decisions are fast; scope problems surface within days.
- Cover letter framing — editors use it to judge fit before reading the manuscript.
How to approach JAMA Oncology
Use the submission guide like a working checklist. The goal is to make fit, package completeness, and cover-letter framing obvious before you open the portal.
Stage | What to check |
|---|---|
1. Scope | Presubmission inquiry (rarely used) |
2. Package | Full submission |
3. Cover letter | Editorial and statistical review |
4. Final check | Peer review |
Quick answer: Oncology Submitting to JAMA Oncology is less about navigating a portal and more about proving that the paper belongs in a very selective oncology conversation. The mechanics of submission are manageable. The difficult part is whether the manuscript reads like a paper that can influence oncology practice, interpretation of cancer evidence, or major decision-making in the field.
The journal is not looking for a competent oncology manuscript in the abstract. It is looking for a manuscript whose methods, endpoints, and clinical consequences are strong enough to justify attention from a broad, high-level cancer audience.
From our manuscript review practice
Of manuscripts we've reviewed for JAMA Oncology, papers failing to clearly rank Key Points by clinical consequence, with endpoints mixed across tables and supplementary materials rather than hierarchically presented, trigger desk rejection. Reviewers expect the primary endpoint, secondary endpoints, and exploratory findings to be visually distinct in the results.
What this page is for
This page is about package readiness, not post-upload workflow.
Use it when you are still deciding:
- whether the manuscript is built with enough reporting discipline for a JAMA Network journal
- whether the Key Points, abstract, and title make the clinical consequence obvious enough
- whether the endpoint hierarchy and statistics are stable enough
- whether the package is mature enough for very fast editorial triage
If you want the actual workflow after upload, early statuses, and where papers usually stall, that belongs on the submission-process page.
What should already be in the package
Before you submit to JAMA Oncology, the package should already communicate four things cleanly:
- what the main oncology question is
- why the result matters to a broad oncology audience
- which endpoint or evidence line carries the real claim
- why the conclusion is proportionate to the design
At a minimum, that means:
- Key Points that state the clinical or interpretive consequence plainly
- a structured abstract that does not hide the real result
- endpoint hierarchy that is stable and easy to follow
- figures and tables that make the primary finding legible quickly
- reporting-guideline support, ethics language, disclosures, and registrations ready before upload
This is where many otherwise strong oncology papers still look unfinished.
What the official author guidance makes explicit
JAMA Oncology is less forgiving about submission structure than many oncology journals. The live instructions make several requirements explicit for Original Investigations:
- 3000-word main-text limit
- no more than 5 tables and/or figures
- structured abstract
- Key Points
- Data Sharing Statement
- EQUATOR reporting compliance
The same instructions also state that Study Protocols with Statistical Analysis Plans are required for randomized and nonrandomized clinical trials and encouraged for other study types. That is important because JAMA Oncology is not simply asking for a clean story. It is asking for a package that looks statistically and operationally ready on day one.
Package mistakes that trigger early rejection
The most common pre-peer-review problems are not portal problems. They are package problems.
- The abstract is technically correct but editorially vague. Editors should not have to infer why the paper matters.
- Key Points read like marketing copy. If the summary language overclaims, trust drops immediately.
- Primary versus secondary findings are blurred. JAMA Oncology is not forgiving when the argument depends on exploratory material.
- The audience case is too narrow. A good disease-site paper can still feel wrong for this journal if the broader oncology consequence is weak.
- The supplement is carrying too much of the paper's logic. The main manuscript should already feel stable and interpretable.
Before you open the submission portal
Work through this checklist first:
- confirm that the manuscript has relevance beyond one institutional experience or narrow technical niche
- make sure the abstract states the clinical question, design, and real implication clearly
- verify that primary endpoints, subgroup logic, and statistical hierarchy are easy to follow
- check trial, observational, or translational reporting against the right guideline before upload
- prepare a cover letter that explains editorial significance, not just novelty
- clean up ethics, trial registration, funding, conflict, and author contribution fields before you start
At JAMA Oncology, small weaknesses in framing or methodology become large editorial weaknesses quickly because the comparison set is so strong.
Step-by-step submission flow
Step | What to do | What usually goes wrong |
|---|---|---|
1. Confirm article type and fit | Make sure the paper belongs in the journal's clinical oncology audience. | Authors submit specialty work that would land more naturally in a narrower oncology title. |
2. Finalize title, abstract, and key messages | Make the patient or practice consequence visible immediately. | The paper sounds scientifically respectable but clinically too incremental. |
3. Prepare manuscript, tables, and supplement | Organize endpoints, population definitions, and reporting checklists clearly. | Key protocol or methods detail is spread across supplement files rather than made legible in the main paper. |
4. Enter metadata, disclosures, and registrations | Complete trial registration, ethics, funding, conflicts, and author information carefully. | Admin cleanup delays the file and makes the package feel less mature. |
5. Review system proofs and file integrity | Check tables, references, figure quality, and appendix labeling. | Oncology manuscripts often carry dense tables that become confusing in proof form. |
6. Submit and respond quickly to editorial questions | Answer any requests for file cleanup or clarification immediately. | Slow responses can hurt momentum on a journal that moves fast at the first screen. |
The portal itself is not the real barrier. The manuscript has to look like a major oncology paper before the editor sends it any further.
What editors are actually screening for
Editorial screen | Pass | Desk-rejection trigger |
|---|---|---|
Clinical consequence | Paper changes treatment choice, risk interpretation, care delivery, or meaningful understanding of cancer outcomes; the practical implication is visible from the first page | Clinical implication is real within a narrow disease niche but does not establish why a broad oncology audience should care; consequence requires specialist context to become persuasive |
Methodological discipline | Inferential structure is stable; conclusions follow from pre-specified endpoints; subgroup reasoning is clearly flagged and supported by adequate power | Conclusions lean heavily on exploratory findings, limited validation, or unstable subgroup reasoning; the paper looks risky when the endpoint hierarchy is examined carefully |
Audience breadth | Paper matters to a broad oncology readership even when disease-specific; the clinical or interpretive consequence extends beyond one tumor type or biomarker niche | Result is excellent within one disease corner but the manuscript does not make a convincing case that the broader oncology field should change practice or interpretation |
Reporting maturity | Protocol discipline, endpoint clarity, trial or cohort transparency, and consistency across tables, supplement, and discussion are already visible before peer review | Tables, supplement, protocol logic, and discussion are not perfectly aligned; the package looks fragile when compared against reporting-guideline requirements for the study type |
Common mistakes and avoidable delays
The same avoidable issues show up repeatedly:
- treating a good specialty result as if it automatically belongs in a top-tier general oncology venue
- overinterpreting secondary endpoints or exploratory analyses
- using a title and abstract that hide the real strength or weakness of the evidence
- failing to make the clinical implication visible on the first page
- letting the supplement carry too much of the methods logic
- writing a cover letter that sounds promotional rather than editorially precise
Most of these are submission problems, not review problems. Editors can see them quickly.
Readiness check
Run the scan while JAMA Oncology's requirements are in front of you.
See how this manuscript scores against JAMA Oncology's requirements before you submit.
What a stronger JAMA Oncology package looks like
A stronger package usually has:
- a first page that makes the patient or practice consequence visible
- clean hierarchy between primary, secondary, and exploratory analyses
- tables that help a busy oncology editor orient immediately
- a discussion that respects limits while still arguing why the study matters
- a cover letter that explains why the paper belongs in JAMA Oncology specifically
- supplementary materials that support, but do not rescue, the main paper
That is important because many rejected papers are not weak studies. They are papers that have not yet been packaged for the level of editorial scrutiny the journal applies.
What should already be assembled before upload
Before the file enters the system, the package should already be operationally complete enough that the editor can judge the study rather than chase missing pieces.
That usually means:
- title page, structured abstract, and Key Points already aligned around the same claim
- protocol and statistical analysis plan ready as supplemental files when required
- reporting checklists prepared for the actual study type
- disclosures, trial registration, ethics, and data-sharing language already finalized
- tables and figures edited for fast interpretation by a broad oncology editor, not just a disease-site expert
At this journal, those details are part of the credibility signal, not just admin cleanup.
What a strong cover letter includes
Cover letter element | What strong looks like |
|---|---|
Why the question matters now | States what decision, practice pattern, or evidence gap the study changes; the editor does not have to infer the practical consequence from the methods section |
Why the design deserves confidence | Explains the specific methodological strength directly: trial discipline, external validation, careful cohort design, or a particularly strong endpoint strategy |
Why the audience is broad enough | Shows why the paper matters beyond one disease corner, biomarker niche, or institutional setting without overclaiming generalizability the data cannot support |
Why JAMA Oncology is the right venue | Explains why the paper belongs here rather than at Journal of Clinical Oncology, Lancet Oncology, Cancer Discovery, or a strong disease-specific title; the argument should be about readership fit, not prestige |
A practical readiness check
Before submitting, ask these blunt questions:
- Is the main clinical or interpretive consequence visible on page one?
- Would the paper still look strong if the exploratory findings were removed?
- Is the conclusion appropriately scaled to the evidence?
- Does the package feel like a high-priority oncology submission, not just a worthy one?
If several answers are uncertain, the safer move is to strengthen the paper before upload.
Where authors usually lose the editor
Failure | What it looks like |
|---|---|
Paper is sound but too narrow | Good oncology science, but the relevance is confined to one disease site, biomarker population, or institutional experience without a convincing argument for broader field impact |
Narrative is stronger than the data | Abstract and cover letter suggest a practice-changing result, but the primary evidence rests on exploratory analyses, modest effect sizes, or subgroup findings that are underpowered for the claim |
Package is not fully ready | Tables, supplement, protocol logic, and discussion pull in slightly different directions; the manuscript looks more fragile under careful reading than the summary language suggests |
What to check before final submission
Before pressing submit, make sure:
- the title and abstract state the actual implication clearly
- primary versus exploratory analyses are unmistakable
- tables support quick interpretation rather than slow decoding
- limitations are honest and visible
- the supplement supports the paper without carrying the main logic
- the cover letter makes the editorial case with discipline
At this level, strong packaging is not a cosmetic advantage. It is part of the scientific credibility signal.
How to decide whether JAMA Oncology is the right venue
Scenario | Best move |
|---|---|
Paper changes interpretation or care for a broad oncology audience | Submit to JAMA Oncology; the editorial case is strongest when the consequence extends beyond one tumor type or disease niche |
Audience is genuinely specialized despite strong science | Choose a narrower oncology title; a high-impact specialty journal is a better outcome than a JAMA Oncology desk rejection |
Paper also fits Journal of Clinical Oncology or Lancet Oncology | Explain the JAMA Oncology fit explicitly in the cover letter; broad oncology reach and JAMA Network reporting discipline are the strongest arguments |
Policy or health equity angle is central to the paper | JAMA Oncology is a reasonable target; the journal publishes policy, practice, and access work when the cancer consequence is clear |
Choose another top-tier venue only if the editorial identity is better aligned
Some papers fit better where policy, general medicine, or ultra-high-impact novelty is the primary frame. The submission decision should be driven by editorial fit, not by abstract prestige logic.
That comparison is useful because it forces the paper to justify why this is the right audience now rather than simply a desirable logo.
Submit If
- the paper changes how an oncology reader thinks or acts
- the primary evidence is strong enough to stand on its own
- the package is clean, mature, and editorially focused
- the audience is broader than one narrow disease subgroup
- the manuscript looks ready for high-level scrutiny
Fix first if
- the paper depends on secondary or exploratory findings for excitement
- the clinical consequence is still vague or delayed until the discussion
- the audience case is too narrow for a broad oncology title
- the methods logic is split awkwardly across main text and supplement
- the paper feels good but not yet definitive
Before you upload, run your manuscript through a JAMA Oncology submission readiness check to catch the issues editors filter for on first read.
Related JAMA Oncology resources: JAMA Oncology submission process.
Is JAMA Oncology the right target for your paper?
JAMA Oncology (IF 20.1, 5-year IF 24.7, JCR 2024) publishes roughly 122 original articles per year, making it one of the most selective oncology journals in the world. It's ranked 14th out of 326 journals in Oncology.
The journal follows AMA style and requires ICMJE compliance, structured abstracts, and Key Points. If your paper doesn't meet those structural requirements on submission day, it won't survive triage regardless of the science.
Submit here if your paper changes how a broad oncology audience interprets evidence or makes clinical decisions, the endpoint hierarchy is clean, and the reporting package is fully mature.
Choose a narrower oncology journal if the audience is genuinely one disease site, the clinical consequence requires specialist context to appreciate, or the methods logic still depends on supplementary material to hold together.
Last verified against AMA author guidelines, ICMJE recommendations, and Clarivate JCR 2024 (IF 20.1, JCI 4.53, Q1, rank 14/326 in Oncology).
In our pre-submission review work with manuscripts targeting JAMA Oncology
In our pre-submission review work with manuscripts targeting JAMA Oncology, three patterns generate the most consistent desk rejections among the papers we analyze.
In our experience, roughly 35% of desk rejections at JAMA Oncology trace to scope or framing problems that prevent the paper from competing in this venue. In our experience, roughly 25% involve insufficient methodological rigor or missing validation evidence. In our experience, roughly 20% arise from a novelty claim that outpaces the supporting data.
- Key Points that fail to state a practice-changing consequence. JAMA Oncology's author instructions require Key Points that communicate "the importance of this study" to a broad oncology audience, and we see consistent rejection of packages where the Key Points restate what was measured rather than what changed. A Key Point reading "We performed a retrospective analysis of 850 patients with stage III non-small cell lung cancer" tells an editor what was done. A Key Point reading "Adjuvant pembrolizumab reduced 5-year recurrence by 18 percentage points in PD-L1-high resected NSCLC, a finding that could affect standard of care for approximately 40,000 US patients annually" tells an editor what changed. The gap between these two approaches is the desk rejection rate for otherwise strong oncology papers.
- Primary and secondary endpoints that collapse under editorial scrutiny. We observe that many JAMA Oncology submissions present exploratory analyses or secondary endpoints as if they carry the paper's main claim, often because the primary endpoint result was more modest than authors expected. JAMA Network journals apply strict inferential hierarchy: the paper's conclusion must follow from its pre-specified primary endpoint. We see this most often in biomarker papers where the molecularly stratified subgroup outperforms the intention-to-treat analysis. Editors recognize this pattern and desk-reject rather than let it become a reviewer debate.
- Reporting checklists submitted as afterthoughts rather than structural guides. JAMA Oncology requires EQUATOR-compliant reporting for the study type, and we observe that manuscripts where CONSORT, STROBE, or REMARK checklists were completed after writing, rather than used to structure the paper, contain predictable gaps: sequence generation and allocation concealment described vaguely in RCTs, selection criteria inconsistent between Methods and Supplementary Table 1 in cohort studies, statistical analysis plans missing for prospective designs. Editors at JAMA Network journals check these checklists against the manuscript text before sending to review.
Clarivate JCR 2024 bibliometric data provides additional benchmarks when evaluating journal fit.
SciRev author-reported data confirms JAMA Oncology's approximately 21-day median to first decision. A JAMA Oncology submission readiness check can evaluate whether your Key Points, endpoint hierarchy, and reporting checklist alignment meet the journal's triage standard before you upload.
Submit If
- the paper demonstrates clinical consequence visible on page one: changes treatment choice, risk interpretation, care delivery, or meaningful understanding of cancer outcomes for broad oncology audience
- Key Points clearly state practice-changing results rather than restating what was measured, and primary endpoint reasoning is stable and easy to follow from the endpoint hierarchy
- methodological discipline is evident: conclusions follow from pre-specified primary endpoints, subgroup reasoning is clearly flagged, and reporting aligns with guideline requirements
- the manuscript is fully mature with protocol, statistical analysis plan, ethics, trial registration, and reporting checklists ready at submission
Think Twice If
- the clinical consequence, while real, is confined to one narrow disease niche without convincing argument that the broad oncology audience should change practice or interpretation
- the conclusion relies on secondary endpoints or exploratory findings because the primary endpoint result was more modest than expected
- Key Points read like a summary rather than stating the specific practice-changing consequence, or the patient consequence requires specialist context to appreciate
- tables and supplementary materials carry significant portions of the paper's logic rather than the main manuscript being stable and fully interpretable on its own
Frequently asked questions
Submit through the JAMA Network submission portal. Before uploading, ensure your manuscript has strong Key Points, a structured abstract with clear endpoint logic, and stable reporting materials. The package should communicate the main oncology question, why results matter to a broad oncology audience, which endpoint carries the real claim, and that methods are disciplined enough for a JAMA Network journal.
JAMA Oncology looks for manuscripts that can influence oncology practice, interpretation of cancer evidence, or major decision-making. The journal requires strong methods, clear endpoints, and clinical consequences strong enough to justify attention from a broad, high-level cancer audience. It is not looking for merely competent oncology work.
JAMA Oncology is very selective with fast editorial triage. The journal requires reporting discipline consistent with JAMA Network standards, including structured abstracts, Key Points, and clear endpoint hierarchies. Many submissions are rejected before peer review if the clinical consequence is not immediately visible.
Common reasons include insufficient reporting discipline for a JAMA Network journal, Key Points or abstract that fail to make the clinical consequence obvious, unstable endpoint hierarchy or statistics, a package that is not mature enough for fast editorial triage, and manuscripts better suited to a specialty oncology journal.
Sources
Final step
Submitting to JAMA Oncology?
Run the Free Readiness Scan to see score, top issues, and journal-fit signals before you submit.
Anthropic Privacy Partner. Zero-retention manuscript processing.
Where to go next
Start here
Same journal, next question
- how to avoid desk rejection at JAMA Oncology
- JAMA Oncology submission process
- Is Your Paper Ready for JAMA Oncology? The Broadest Elite Oncology Journal
- JAMA Oncology Review Time: What Authors Can Actually Expect
- JAMA Oncology Acceptance Rate: What Authors Can Use
- JAMA Oncology Impact Factor 2026: 20.1, Q1, Rank 14/326
Supporting reads
Conversion step
Submitting to JAMA Oncology?
Anthropic Privacy Partner. Zero-retention manuscript processing.